Literature DB >> 18560513

Cannabis use and the risk of developing a psychotic disorder.

Wayne Hall1, Louisa Degenhardt.   

Abstract

WE BRIEFLY REVIEW THE EVIDENCE THAT CANNABIS USE IN ADOLESCENCE AND YOUNG ADULTHOOD IS A CONTRIBUTORY CAUSE OF SCHIZOPHRENIFORM PSYCHOSES, BY SUMMARISING LONGITUDINAL STUDIES THAT: a) have examined relationships between cannabis use and the risk of psychosis or psychotic symptoms; and b) have controlled for potential confounders, such as other forms of drug use and personal characteristics that predict an increased risk of psychosis. There is now reasonable evidence from longitudinal studies that regular cannabis use predicts an increased risk of schizophrenia and of reporting psychotic symptoms. These relationships have persisted after controlling for confounding variables such as personal characteristics and other drug use. The relationships did not seem to be explained by cannabis being used to self-medicate symptoms of psychosis. A contributory causal relationship is biologically plausible because psychotic disorders involve disturbances in the dopamine neurotransmitter system with which the cannabinoid system interacts, as has been shown by animal studies and a human provocation study. We briefly explore the clinical and public health implications of the most plausible hypothesis, that cannabis use precipitates schizophrenia in persons who are vulnerable because of a personal or family history of schizophrenia.

Entities:  

Keywords:  Cannabis, psychosis; adolescents; dopamine; educational interventions; schizophrenia

Year:  2008        PMID: 18560513      PMCID: PMC2424288          DOI: 10.1002/j.2051-5545.2008.tb00158.x

Source DB:  PubMed          Journal:  World Psychiatry        ISSN: 1723-8617            Impact factor:   49.548


  43 in total

1.  The association between psychosis and problematical drug use among Australian adults: findings from the National Survey of Mental Health and Well-Being.

Authors:  L Degenhardt; W Hall
Journal:  Psychol Med       Date:  2001-05       Impact factor: 7.723

2.  Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study.

Authors:  Louise Arseneault; Mary Cannon; Richie Poulton; Robin Murray; Avshalom Caspi; Terrie E Moffitt
Journal:  BMJ       Date:  2002-11-23

3.  Testing hypotheses about the relationship between cannabis use and psychosis.

Authors:  Louisa Degenhardt; Wayne Hall; Michael Lynskey
Journal:  Drug Alcohol Depend       Date:  2003-07-20       Impact factor: 4.492

4.  Cannabis use and psychosis.

Authors:  W Hall
Journal:  Drug Alcohol Rev       Date:  1998-12

Review 5.  Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors.

Authors:  P T Männistö; S Kaakkola
Journal:  Pharmacol Rev       Date:  1999-12       Impact factor: 25.468

6.  Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction.

Authors:  Deepak Cyril D'Souza; Walid Michel Abi-Saab; Steven Madonick; Kimberlee Forselius-Bielen; Anne Doersch; Gabriel Braley; Ralitza Gueorguieva; Thomas B Cooper; John Harrison Krystal
Journal:  Biol Psychiatry       Date:  2005-03-15       Impact factor: 13.382

7.  The temporal dynamics of relationships between cannabis, psychosis and depression among young adults with psychotic disorders: findings from a 10-month prospective study.

Authors:  Louisa Degenhardt; Chris Tennant; Stuart Gilmour; David Schofield; Louise Nash; Wayne Hall; Diana McKay
Journal:  Psychol Med       Date:  2007-02-09       Impact factor: 7.723

Review 8.  Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review.

Authors:  Theresa H M Moore; Stanley Zammit; Anne Lingford-Hughes; Thomas R E Barnes; Peter B Jones; Margaret Burke; Glyn Lewis
Journal:  Lancet       Date:  2007-07-28       Impact factor: 79.321

9.  Cannabis and schizophrenia: model projections of the impact of the rise in cannabis use on historical and future trends in schizophrenia in England and Wales.

Authors:  Matthew Hickman; Peter Vickerman; John Macleod; James Kirkbride; Peter B Jones
Journal:  Addiction       Date:  2007-04       Impact factor: 6.526

Review 10.  The catechol-O-methyltransferase polymorphism: relations to the tonic-phasic dopamine hypothesis and neuropsychiatric phenotypes.

Authors:  Robert M Bilder; Jan Volavka; Herbert M Lachman; Anthony A Grace
Journal:  Neuropsychopharmacology       Date:  2004-11       Impact factor: 7.853

View more
  31 in total

1.  Perspective: Be clear about the real risks.

Authors:  Matthew Hill
Journal:  Nature       Date:  2015-09-24       Impact factor: 49.962

Review 2.  Cannabinoids and Schizophrenia: Risks and Therapeutic Potential.

Authors:  Marc W Manseau; Donald C Goff
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

3.  Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitalization.

Authors:  Daniel J Foti; Roman Kotov; Lin T Guey; Evelyn J Bromet
Journal:  Am J Psychiatry       Date:  2010-05-17       Impact factor: 18.112

Review 4.  Neurobiological consequences of maternal cannabis on human fetal development and its neuropsychiatric outcome.

Authors:  Didier Jutras-Aswad; Jennifer A DiNieri; Tibor Harkany; Yasmin L Hurd
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-07-02       Impact factor: 5.270

5.  Do we have any solid evidence of clinical utility about the pathophysiology of schizophrenia?

Authors:  Stephen M Lawrie; Bayanne Olabi; Jeremy Hall; Andrew M McIntosh
Journal:  World Psychiatry       Date:  2011-02       Impact factor: 49.548

6.  Astrocytic Mechanisms Involving Kynurenic Acid Control Δ9-Tetrahydrocannabinol-Induced Increases in Glutamate Release in Brain Reward-Processing Areas.

Authors:  Maria E Secci; Paola Mascia; Claudia Sagheddu; Sarah Beggiato; Miriam Melis; Andrea C Borelli; Maria C Tomasini; Leigh V Panlilio; Charles W Schindler; Gianluigi Tanda; Sergi Ferré; Charles W Bradberry; Luca Ferraro; Marco Pistis; Steven R Goldberg; Robert Schwarcz; Zuzana Justinova
Journal:  Mol Neurobiol       Date:  2018-08-27       Impact factor: 5.590

7.  Impact of first episode psychosis treatment on heavy cannabis use: Secondary analysis on RAISE-ETP study.

Authors:  Karl C Alcover; Oladunni Oluwoye; Liat Kriegel; Sterling McPherson; Michael G McDonell
Journal:  Schizophr Res       Date:  2019-08-02       Impact factor: 4.939

Review 8.  Cannabis Epidemiology: A Selective Review.

Authors:  James C Anthony; Catalina Lopez-Quintero; Omayma Alshaarawy
Journal:  Curr Pharm Des       Date:  2017-01-04       Impact factor: 3.116

Review 9.  The analgesic potential of cannabinoids.

Authors:  Jaseena Elikkottil; Jaseena Elikottil; Pankaj Gupta; Kalpna Gupta
Journal:  J Opioid Manag       Date:  2009 Nov-Dec

10.  Cannabidiol, a nonpsychotropic component of cannabis, inhibits cue-induced heroin seeking and normalizes discrete mesolimbic neuronal disturbances.

Authors:  Yanhua Ren; John Whittard; Alejandro Higuera-Matas; Claudia V Morris; Yasmin L Hurd
Journal:  J Neurosci       Date:  2009-11-25       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.